Skip to content

Author

A. Tauziède-Espariat

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.

BACKGROUND MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities. METHODS We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...

Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al. · 0 citations
Sep 2026

[New developments in grading of astrocytomas, IDH-mutant: Study of the impact of update 12 of cIMPACT-NOW].

INTRODUCTION The 2021 World Health Organisation (WHO) classification of the Central Nervous System tumors introduced, for the first time, a molecular biomarker (homozygous deletion of CDKN2A/B) into the grading of astrocytomas, IDH-mutant. Since then, the cIMPACT-NOW expert group has proposed a new prognostic algorithm...

A. Tauziède-Espariat, Alice Métais, F. Sassi et al. · 0 citations
Aug 2026

DNMT3B plays antagonistic roles with SMARCB1 and is a targetable vulnerability in rhabdoid tumors.

PURPOSE Rhabdoid tumors (RTs) are highly aggressive pediatric cancers driven by the biallelic inactivation of the SMARCB1 tumor suppressor gene, the sole recurrent genetic alteration. SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex; its loss disrupts epigenetic gene regulation, supporting the...

C. Chauvin, Ryszard Wimmer, Ludovica Brunetti et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.